Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Why Markets Cut Short the Rally of fuboTV Stock

By Chris Lau, InvestorPlace Contributor

fuboTV reported impressive revenue, benefiting from strong subscribers growth. Investors should consider buying FUBO stock.

Chinese Regulators Are Alibaba Stock’s Only Problem

By Chris Lau, InvestorPlace Contributor

BABA stock is underperforming as regulators impose stricter restrictions on the tech sector, hurting the firm and its corporate customers.

7 Best Fintech Stocks to Buy as Digital Transactions Dominate

By Chris Lau, InvestorPlace Contributor

The price of Fintech stocks are about to rise to the upside as the post-pandemic reopening gathers steam, accelerating by Q4.

Revenue Acceleration Will Lift Senseonics

By Chris Lau, InvestorPlace Contributor

Senseonics is ready to launch Eversense CGM systems globally through its partner. Investors buying SENS stock now will get rewarded.

Avoid Clover Health Stock As Its Losses Mount

By Chris Lau, InvestorPlace Contributor

CLOV stock will continue to fade lower as operating costs rise and the digital transformation is anything but proven.

Load More